WuXi Biologics (Cayman) Inc. (WXXWY) Stock Price & Analysis
WuXi Biologics (Cayman) Inc. (WXXWY) — price $13.95 (-2.45%), as of the Oct 2, 2026 trading session; market cap $28.6B. Expected results Mar 23, 2027.
Educational signal · not a buy or sell recommendation · How to read this
WuXi Biologics (Cayman) Inc. · WXXWY · Healthcare · Biotechnology
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore is not published for this security.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $13.95 | |
| Change on the day | -2.45% | |
| 52-week range | $7.30 – $14.44 | |
| Market capitalisation | $28.6B | |
| Price / earnings (trailing) | 38.93 | |
| Shares traded on the day | 699 | |
| Beta (volatility vs the S&P 500) | 0.6 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
The provider's estimated date can change.
What to watch nextOther perspectives
Council score for WuXi Biologics (Cayman) (WXXWY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
9-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Sep 7, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the WXXWY film — every key number, told as a short cinematic story
~2 min · open the film
What is WuXi Biologics (Cayman) (WXXWY), and what does it report?
Short answer · as of
WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. WuXi Biologics (Cayman) Inc. (WXXWY) is classified as Healthcare / Biotechnology. Headquarters: No. 108, Meiliang Road, Wuxi, JS, 214092, CN. It employs 13,252 people and is led by Zhisheng Chen. In Q2 FY2026 it reported revenue of $1.74B and net income of $360M. The market values it at $28.6B.
What do the latest results show for WuXi Biologics (Cayman) (WXXWY)?
Short answer · as of
The most recent reported quarter, Q2 FY2026, carried revenue of $1.74B. Against analyst estimates the company has EPS beat 5 of 8 reports.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $1.75B Aug 25, 2026
- Latest report · revenue estimate
- $1.70B Aug 25, 2026
- Latest report · revenue vs estimate
- Above estimate Aug 25, 2026
- Latest report · EPS vs estimate
- Above estimate Aug 25, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Aug 25, 2026 | $1.75B | $1.70B | $0.1726 | $0.1330 |
| Mar 24, 2026 | $1.66B | $1.71B | $0.1801 | $0.1823 |
| Aug 19, 2025 | $1.39B | $1.36B | $0.1532 | $0.1254 |
| Mar 25, 2025 | $1.39B | $1.32B | $0.0619 | $0.1203 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q2 FY2026 | $1.74B | $360M | $0.17 (diluted) |
| Q4 FY2025 | $1.73B | $376M | $0.18 (diluted) |
| Q2 FY2025 | $1.48B | $349M | $0.16 (diluted) |
| Q4 FY2024 | $1.51B | $277M | $0.13 (diluted) |
What are the financial strengths and risks for WuXi Biologics (Cayman) (WXXWY)?
Short answer
The distress and quality screens read Altman Z 12.31 · Piotroski F 9. Trailing ratios: ROE 10.5% · ROA 7.7% · current ratio 3.04 · earnings yield 2.6% · free-cash-flow yield 2.2%.
What should you watch next at WuXi Biologics (Cayman) (WXXWY)?
Short answer · as of
The next earnings report is expected on Mar 23, 2027.
What the records here don't tell us
- Detailed statement figures are not shown because their conversion to USD has not been verified.
- No insider Form 4 transaction falls inside the window this page reads.
Checked against the records this page reads, on the dates shown above.
How is WuXi Biologics (Cayman) scored?
Research dated 2026-09-12.
WuXi Biologics differs from a drug developer centered on its own pipeline and from a pure-play contract manufacturer confined to production. Its offering reaches from discovery and technical advice through testing, clinical support, commercial manufacturing, vaccine contract services and materials supply across major biopharmaceutical regions.
That breadth lets client work appear at different stages of a molecule’s lifecycle and gives WuXi opportunities to remain involved as programs progress. The dedicated WuXi Vaccines leadership structure also shows that vaccines sit within a broader biologics service organization rather than defining the whole company.
| Company | Price | Market value | Score |
|---|---|---|---|
| $116.23 Oct 2, 2026 | $12.6B | — 5-pillar · not comparable | |
| $2.85 Oct 2, 2026 | $107M | — 5-pillar · not comparable | |
| $0.62 Oct 2, 2026 | — | — 5-pillar · not comparable | |
| $2.34 Sep 15, 2026 | $1.14B | — Model unavailable | |
| $219.72 Oct 2, 2026 | $29.4B | — 5-pillar · not comparable | |
| $57.16 Oct 2, 2026 | $25.3B | — 5-pillar · not comparable | |
| $115.30 Oct 2, 2026 | $23.4B | — 5-pillar · not comparable | |
| $541.70 Oct 2, 2026 | $23.0B | — 5-pillar · not comparable | |
| $58.39 Oct 2, 2026 | $14.7B | — 5-pillar · not comparable | |
| $143.18 Oct 2, 2026 | $14.4B | — 5-pillar · not comparable | |
| $919.21 Oct 2, 2026 | $57.2B | — 5-pillar · not comparable | |
| $227.87 Oct 2, 2026 | $14.2B | — 5-pillar · not comparable |
The comparison model is unavailable. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
What has been published about WuXi Biologics (Cayman) (WXXWY)?
What Investors Ask About WuXi Biologics (Cayman) (WXXWY) — Healthcare
Research dated 2026-09-12; the answers below are from that research, and the full attribution is under Sources. The last question is answered from this page's own dated data, not from the research.
Is WuXi Biologics a drug owner or an outsourced development partner?
WuXi Biologics is primarily an outsourced partner serving drug-company clients from discovery through large-scale manufacturing. Its revenue therefore tracks client development and production work rather than dependence on sales from an internally owned medicine portfolio.
How does WuXi Vaccines fit within WuXi Biologics?
WuXi Vaccines extends the group’s contract development and manufacturing model into vaccines. Dedicated leadership for that operation sits alongside the wider biologics research, development and manufacturing platform.
What is the WXXWY stock price today?
The last price recorded on this page for WuXi Biologics (Cayman) Inc. (WXXWY) is $13.95, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (40 figures)
The 40 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 33 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $13.95 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-04T14:44:40.694Z. | |
px.change | Change on the day | -2.45% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $28.6B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-04T14:44:39.131Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
earn.next | Next earnings date | Mar 23, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
id.business_summary | Business description (FMP excerpt) | WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. | FMP | Financial Modeling Prep (FMP) company profile — Deterministic excerpt derived from id.description; source and date describe the input fact, not a new provider observation | |
px.change_abs | Change on the day, in dollars | −$0.35 | FMP | Financial Modeling Prep (FMP) · quote | |
px.pe | Price / earnings (trailing) | 38.93 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 699 | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.6 | FMP | Financial Modeling Prep (FMP) company profile | |
id.sector | Sector / industry (provider taxonomy) | Healthcare / Biotechnology | FMP | Financial Modeling Prep (FMP) company profile | |
id.hq | Headquarters | No. 108, Meiliang Road, Wuxi, JS, 214092, CN | FMP | Financial Modeling Prep (FMP) company profile | |
id.employees | Employees | 13,252 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Zhisheng Chen | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
fin.q_revenue | Revenue, Q2 FY2026 | $1.74B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
fin.q_income | Net income, Q2 FY2026 | $360M | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
id.founder | Founder named in the filing | Ge Li — Founder & Chairman | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
earn.history.depth.2026-08-25.revenue_actual | Revenue · reported — report date 2026-08-25 | $1.75B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-25.revenue_estimated | Revenue · estimate — report date 2026-08-25 | $1.70B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-25.eps_actual | EPS · reported — report date 2026-08-25 | $0.1726 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-08-25.eps_estimated | EPS · estimate — report date 2026-08-25 | $0.1330 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-24.revenue_actual | Revenue · reported — report date 2026-03-24 | $1.66B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-24.revenue_estimated | Revenue · estimate — report date 2026-03-24 | $1.71B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-24.eps_actual | EPS · reported — report date 2026-03-24 | $0.1801 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-03-24.eps_estimated | EPS · estimate — report date 2026-03-24 | $0.1823 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-19.revenue_actual | Revenue · reported — report date 2025-08-19 | $1.39B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-19.revenue_estimated | Revenue · estimate — report date 2025-08-19 | $1.36B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-19.eps_actual | EPS · reported — report date 2025-08-19 | $0.1532 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-08-19.eps_estimated | EPS · estimate — report date 2025-08-19 | $0.1254 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-25.revenue_actual | Revenue · reported — report date 2025-03-25 | $1.39B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-25.revenue_estimated | Revenue · estimate — report date 2025-03-25 | $1.32B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-25.eps_actual | EPS · reported — report date 2025-03-25 | $0.0619 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2025-03-25.eps_estimated | EPS · estimate — report date 2025-03-25 | $0.1203 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q2 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed |
UNRECORDED — 4 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.range52 | 52-week range | $7.30 – $14.44 | UNRECORDED | Stored company-profile observation — Captured 2026-10-03 | |
earn.history | Reported versus estimated, recent quarters | EPS beat 5 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-10 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 12.31 · Piotroski F 9 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-05 | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE 10.5% · ROA 7.7% · current ratio 3.04 · earnings yield 2.6% · free-cash-flow yield 2.2% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 2 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history.depth.2026-08-25.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($1.75B) with the recorded estimate ($1.70B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-08-25.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.1726) with the recorded estimate ($0.1330) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 1 fact from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
gap.statement_currency | Statement currency limitation | Detailed statement figures are not shown because their conversion to USD has not been verified. | OURS | Stock Expert AI currency-basis check |
Fact-family notes
- Earnings-history note. Source series as of 2026-08-25. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-08-25.revenue_actual,earn.history.depth.2026-08-25.revenue_estimated,earn.history.depth.2026-08-25.revenue_actual.comparison,earn.history.depth.2026-08-25.eps_actual.comparison,earn.history.depth.2026-08-25.eps_actual,earn.history.depth.2026-08-25.eps_estimated,earn.history.depth.2026-03-24.revenue_actual,earn.history.depth.2026-03-24.revenue_estimated,earn.history.depth.2026-03-24.eps_actual,earn.history.depth.2026-03-24.eps_estimated,earn.history.depth.2025-08-19.revenue_actual,earn.history.depth.2025-08-19.revenue_estimated,earn.history.depth.2025-08-19.eps_actual,earn.history.depth.2025-08-19.eps_estimated,earn.history.depth.2025-03-25.revenue_actual,earn.history.depth.2025-03-25.revenue_estimated,earn.history.depth.2025-03-25.eps_actual,earn.history.depth.2025-03-25.eps_estimated.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-12
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Sector / industry (provider taxonomy) | Healthcare / Biotechnology | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Business description | WuXi Biologics (Cayman) Inc. delivers integrated solutions covering the entire lifecycle of biological drug development, from initial discovery to full-scale manufacturing. These services are provided to clients worldwide, with a significant presence in China, North America, and Europe. Beyond its core offerings, the company engages in various specialized activities, including offering expert advice on biopharmaceutical technology, managing international sales agreements, and developing and providing advanced testing solutions. It also handles sales and marketing efforts, supports clinical trials and production of biologics, produces and distributes medical goods, operates a contract development and manufacturing organization (CDMO) for vaccines, and supplies essential materials to the industry. Founded in 2014, WuXi Biologics is based in Wuxi, China, and maintains strategic alliances with partners such as ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Named officers | CEO: Zhisheng Chen; Officers: Xuejun Gu — Title: CTO, Chief Client Officer, EVP of Global Biologics Development Department & Executive Director, Pay: $791,572, Born: 1971; Ge Li — Title: Founder & Chairman, Born: 1967; Jijie Gu — Title: Chief Scientific Officer & President of Global Biologics Research, Born: 1966; Jian Dong — Title: Chief Executive Officer of WuXi Vaccines, Born: 1964; Xiaohui Liu — Title: Executive VP & Chief Human Resources Officer; He Wang — Title: General Counsel, Chief Compliance Officer, SVP and Head of Legal & Compliance Department; Lihua Yu — Title: Chief Operating Officer & Senior Vice President; Angus Scott Marshall Turner — Title: Senior Vice President and Head of Global BD & Alliance Management, Born: 1968 Titles and pay come from the company's proxy statement as our provider parsed it. | 2026-09-12 | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) |
| Headquarters | No. 108, Meiliang Road, Wuxi, JS, 214092, CN | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
| Employees | Count: 13,252 | 2026-09-12 | FMP | Financial Modeling Prep (FMP) company profile |
Data provided for informational purposes only.